AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02022748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will receive treatment A in Period 1 and treatment B in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 1. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
Study NCT02022748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 2, subjects will receive treatment B in Period 1 and treatment A in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 2. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
Study NCT02022748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Group B is healthy subjects. Group B healthy subjects will receive oral 90 mg ticagrelor referred to as Treatment H.
Study NCT03706937 — intervention group
Intervention type: OTHER
Intervention: Semi directive interview
Description: Semi directive interview will be performed to try to define the management of addictions in the oncology care course. Thus, an approach in terms of social representations among paramedical professional actors involved in the care of patients treated for cancer and with an unresolved addictive disorder sounds the best way for this research.
Study NCT03287843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision before 56 days (4-8 weeks)
Description: Low anterior resection or abdominoperineal resection
Study NCT03287843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision after 56 days (8-12 weeks)
Description: Low anterior resection or abdominoperineal resection
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, dose to be determined
Description: CORT118335 is supplied as suspension for oral dosing
Study NCT01353872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrattente / Nutraperf / Nutrarecup
Description: 500 mL of Nutrattente before each match 500 mL/h of Nutraperf during each match 250 mL of Nutrarecup after each match
Study NCT01353872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutrattente placebo / Nutraperf placebo / Nutrarecup placebo
Description: 500 mL of Nutrattente placebo before each match 500 mL/h of Nutraperf placebo during each match 250 mL of Nutrarecup placebo after each match
Study NCT03217123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain stimulation
Description: Electrical stimulation at subcortical level
Study NCT03118206 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar traction
Study NCT02922738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VisualDx
Description: VisualDx is a computerized clinical information technology with medical image and text content in dermatology.
Study NCT02018575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crystalline Lysine Amino Acid Mix
Description: Crystalline Lysine from Amino Acid Mixture in amount of 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
Study NCT02018575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White corn meal porridge
Description: A cornmeal porridge including 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
Study NCT01038362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCEP Step 1 diet plus Almonds
Description: NCEP Step 1 Diet Plus Almonds 3 oz per day for 6 weeks
Study NCT03118206 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulation
Study NCT03118206 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Study NCT01038362 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Almonds
Description: NCEP Step 1 diet without almonds
Study NCT02404922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-730
Study NCT02404922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-730
Study NCT00559806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 weeks of unilateral immobilisation and 4 weeks of resistance training
Description: 2 weeks of whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
Study NCT00559806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 weeks of unilateral immobilisation and 4 weeks of resistance training
Description: 2 weeks of unilateral whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
Study NCT01453179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
Study NCT01453179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
Study NCT01886079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
Study NCT01886079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.4 mcg/kg/h, IV
Study NCT04082156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrical stimulation
Description: electrical stimulation
Study NCT04082156 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: no stimulation
Study NCT01447277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic Block
Description: Performing a sciatic block in addition to a femoral block preoperatively
Study NCT01447277 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Femoral Block only
Description: Performing a preoperative sciatic nerve block only
Study NCT04114487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dual task balance training
Description: The studies were planned to be 2 times a week for 12 weeks. The 20-minute Dual Task balance training program is planned to be composed of two sections of 10 minutes. In the first 10 min section, the individual will exercise with the multi-task mode of CogniBoard on the balance ball. . Stroop study will be performed on the balance ball in the second 10 minutes of the exercise.
Study NCT04114487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual task balance training
Description: The studies were planned to be 2 times a week for 12 weeks. The 20-minute Dual Task balance training program is planned to be composed of two sections of 10 minutes. In the first 10 min section, the individual will exercise with the multi-task mode of CogniBoard on the balance ball. . Stroop study will be performed on the balance ball in the second 10 minutes of the exercise.
Study NCT00486031 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Balsalazide Disodium
Study NCT02458209 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bococizumab PFS:Pfizer
Description: 150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Pfizer Andover
Study NCT02458209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bococizumab PFS: BIP
Description: 150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma.
Study NCT02458209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bococizumab PFP
Description: 150 mg bococizumab administered SC in a prefilled pen using drug substance manufactured at Pfizer Andover
Study NCT02035358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute®-Renal (HAR) Immunotherapy
Description: HyperAcute®-Renal Immunotherapy consisting of equal cell doses of each of two allogeneic renal cell cancer cell lines (HAR1 and HAR2) engineered to express the murine α(1,3)GT gene.~Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization.
Study NCT04036838 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PyloPlus UBT System
Description: Breath will be analyzed for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
Study NCT04036838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Histology
Description: Biopsy specimen fixed with 10% buffered formalin were cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist
Study NCT04036838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid Urease Test
Description: Biopsy specimen obtained and placed onto Rapid Urease Test
Study NCT02648022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief mental health interventions and case management
Description: The mental health practitioner (MHP) provided brief interventions and follow up sessions designed to reduce the risk factors that are barriers to successful antiviral treatment (substance use, depression, PTSD. Second, MHP provided ongoing case management services to these patients, with an emphasis on navigating the complex HCV care process, preparation for antiviral treatment, and managing the treatment process (adherence, side effects, etc). Third, the MHP also activated the patient and facilitate the medication management of depression and other psychiatric disorders when possible by collaborating with the prescribing HCV physicians.
Study NCT02485925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL® SMARTTOUCH™
Description: Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH™ contact force sensing catheters (study device)
Study NCT04177420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIR-C mattress
Description: infrared-C irradiation by hot mattress with a powered heating compress
Study NCT04177420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIR-C abdominal pad
Description: infrared-C irradiation by hot abdominal pad with a powered heating compress
Study NCT04177420 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: fake FIR-C mattress
Description: normal mattress with fake controller, custom make for placebo group
Study NCT04177420 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: fake FIR-C abdominal pad
Description: normal abdominal pad with fake controller, custom make for placebo group
Study NCT02270762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest in bed
Study NCT02270762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive verticalization
Study NCT04036838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: H.pylori Culture
Description: Biopsy specimen obtained and sent to lab for culture analysis
Study NCT06032429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Medical Appointments
Description: SMA is a subset of such clinics and are defined by groups of patients meeting over time for comprehensive care for a defining chronic condition or health care state, which involved both a person trained or skilled in delivering patient education or facilitating patient interaction.
Study NCT03166189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow-derived MSC and HRT
Description: * Transplantation procedure to endometrial cavity is performed with ultrasound guidance on menstrual cycle day 5-6 through uterine cervix using cater for embryo transfer with 1 ml of suspension containing 5 millions of autologous bone marrow-derived mesenchymal stem cells~* Three cycles of HRT following MSC transplantation;~* Pipelle-biopsy of endometrium on day 20 of hormonal replacement therapy of the last (third) cycle;~* Frozen/thawed embryo transfer 3-6 months after transplantation.
Study NCT03166189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hormonal replacement therapy
Description: standard treatment of hypoplastic endometrium or Asherman's syndrome:~* Three cycles of HRT preceding frozen/thawed embryo transfer;~* Frozen/thawed embryo transfer.
Study NCT01051856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SEAMGUARD with bioabsorbable staple
Description: In the SEAMGUARD group, pancreatic resection and transection of the pancreatic body will be executed using an endoscopic linear stapling device.
Study NCT01997814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: herbal immunomodulator
Description: Patients in Test Group were treated with scaling and root planing (SRP) along with Herbal Immunomodulators (Septilin) therapy, 2 tablets twice daily for 3 weeks.
Study NCT01997814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in Control Group were treated with scaling and root planing (SRP) along with Placebo therapy, 2 tablets twice daily for 3 weeks.
Study NCT00681564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-Stage Full-Mouth Disinfection
Description: * Scaling and root planing, four quadrants in one session~* Tongue brushing with a 1% chlorhexidine gel (1 minute)~* Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes)~* Subgingival chlorhexidine (1%) irrigation in all pockets~* Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention~* Basic oral hygiene instructions~* Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)
Study NCT00681564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal care
Description: * Basic oral hygiene instructions~* Supragingival plaque removal
Study NCT04039607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive nivolumab as intravenous (IV) infusion.
Study NCT04511598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bellus 3D Face Camera
Description: The depth sensor uses infrared structured light scanning technology to capture depth and the camera on the phone or tablet to capture color texture of the face.
Study NCT04511598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Planmeca ProMax 3D Proface
Description: The lasers scan the facial geometry and the digital cameras capture the color texture of the face.
Study NCT01051856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TissueLink with radiofrequency ablation
Description: After pancreatic transection with the method of choice of the operating surgeon, the pancreatic remnant will be treated with Tissuelink alone for an ablation depth (thickness) of approximately 7 mm.
Study NCT03137433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal-replacement Therapy
Description: We seek to examine the effect of meal-replacement therapy on weight loss outcomes in teens with severe obesity.
Study NCT04755699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Stimulation
Description: The study involves the administration of various electrical pulses being delivered to muscles and/or the spinal column with an investigational neurostimulator to evoke various limb movements in order to improve functional movement.
Study NCT00422591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1.5 g/m2 IV over 24 hours daily on day 1-4 (age \<60 years) or days 1-3 (age > 60 years).
Study NCT00422591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 12 mg/m2 IV over 1 hour daily x 3 (days 1-3)
Study NCT03680950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper Gastrointestinal Monitoring System
Description: Participants will wear a monitoring system consisting of a tiny endoscopy and a mobile device. The endoscopy is inserted to upper gastrointestinal tract via nasal cavity and the mobile device is set to take and send images from the endoscopy to a server for analyzing if the abnormal condition occurs.
Study NCT01729507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Stimulation will be performed with a DC stimulator MC Location of stimulation: Anode over the left dorsolateral cortex, corresponding with F3 (in 10-20 EEG system); cathode over the right temporal cortex Intensity: 2 mA Total duration: Constant stimulation for 20 minutes
Study NCT01729507 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: standardised behavioural therapy
Description: The standardised behavioural therapy will be performed according to the certified Smoke-free programme' of the of the Institute for Therapy Research ('Institut für Therapieforschung', IFT). The course leaders' manual specifies that the ideal number of participants is 8-12.~1 group session for 90 minutes/week for 7 weeks, 2 telephone calls of 10 minutes each, first after the fourth session 3 days after collective smoking cessation, second on day 3 after the last session.
Study NCT01729507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standardised behavioural therapy
Description: The standardised behavioural therapy will be performed according to the certified Smoke-free programme' of the of the Institute for Therapy Research ('Institut für Therapieforschung', IFT). The course leaders' manual specifies that the ideal number of participants is 8-12.~1 group session for 90 minutes/week for 7 weeks, 2 telephone calls of 10 minutes each, first after the fourth session 3 days after collective smoking cessation, second on day 3 after the last session.
Study NCT05545254 — intervention group
Intervention type: GENETIC
Intervention: genetic testing
Description: Two questionnaires were included in the link, one referring to the demographic information, and another one involving the health-promoting lifestyle. In the demographic information, the genetic test results were not requested to be written, but the participants need to answer whether they understand the results. The HPLP-Ⅱ is an scale instrument used to evaluate a person's health-promoting lifestyle behaviors, which contains 52 items and has been translated into Chinese in 1997. It contains 6 subscales: self-actualization, health responsibility, physical activity, nutrition, interpersonal relationships and stress management.
Study NCT02985164 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PDSa
Description: After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSa1 (outside lead apron),PDSa2 (inside lead apron).
Study NCT02985164 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PDSb
Description: After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSb1 (outside lead apron), PDSb2 (inside lead apron).
Study NCT00495170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 2 area under curve (AUC) by vein Weekly
Study NCT00495170 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiotherapy
Description: 2 GY/fraction for 37 fractions (daily treatment, Monday to Friday, for 7.5 weeks).
Study NCT00495170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m\^2 by vein Weekly
Study NCT04755699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Stimulation
Description: The study involves the administration of various electrical pulses being delivered to muscles and/or the spinal column with an investigational neurostimulator to evoke various limb movements in order to improve functional movement.
Study NCT04188522 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetoencephalography (MEG)
Description: Participants will undergo MEG at the University of Maryland (College Park) to measure cerebral activity while performing a visual naming task. The Montreal Cognitive Assessment (MOCA) will also be administered.